Cargando…
Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma
INTRODUCTION: Erythropoiesis-stimulating agent (ESA) treatment has been associated with an increased risk of venous thromboembolism (VTE) in patients with solid tumors and with an increased risk of cardiovascular events in patients with chronic kidney disease. The ESA-related risk in patients with h...
Autores principales: | Horváth-Puhó, Erzsébet, Suttorp, Marit M, Frederiksen, Henrik, Hoekstra, Tiny, Dekkers, Olaf M, Pedersen, Lars, Cannegieter, Suzanne C, Dekker, Friedo W, Sørensen, Henrik Toft |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167129/ https://www.ncbi.nlm.nih.gov/pubmed/30310329 http://dx.doi.org/10.2147/CLEP.S172306 |
Ejemplares similares
-
Effect of Erythropoiesis-Stimulating Agents on Blood Pressure in Pre-Dialysis Patients
por: Suttorp, Marit M., et al.
Publicado: (2013) -
Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patients
por: Suttorp, Marit M, et al.
Publicado: (2013) -
Asthma and risk of myelodysplastic syndromes: a population-based cohort study
por: Frederiksen, Henrik, et al.
Publicado: (2017) -
Antipsychotics and risk of venous thromboembolism: A population-based case-control study
por: Jönsson, Anna K, et al.
Publicado: (2009) -
Impact of venous thromboembolism on the mortality in patients with cancer: a population-based cohort study
por: Sørensen, Henrik Toft, et al.
Publicado: (2023)